SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) NASDAQ:CADL, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the third…

CADL

Related stories